Technical Analysis for ARWR - Arrowhead Research Corporation

Grade Last Price % Change Price Change
grade C 67.32 -1.32% -0.90
ARWR closed down 1.32 percent on Thursday, December 12, 2019, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Very Strong Up Up Down
See historical ARWR trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Multiple of Ten Bearish Other -1.32%
Wide Bands Range Expansion -1.32%
Overbought Stochastic Strength -1.32%
Stochastic Reached Overbought Strength -5.00%
Multiple of Ten Bullish Other -5.00%
Wide Bands Range Expansion -5.00%
Overbought Stochastic Strength -5.00%
Older signals for ARWR ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Arrowhead Research Corporation operates as a clinical stage therapeutics company. It has development programs in oncology, obesity, and chronic hepatitis B virus (HBV) infection. The company assembles a set of technologies, including Dynamic Polyconjugate platform, a RNA delivery system that addresses multiple organ systems and cell types, promotes multi-log gene knockdown in rodents and non-human primates, and induces endosomal escape; and RONDEL, a RNA delivery system for systemic siRNA delivery, and RNAi-mediated mRNA and protein knockdown in human melanoma patients. It also offers Homing Peptides platform, a library of short peptides for the development of peptide-drug conjugates and companion diagnostics. The company's principal product candidates include Adipotide, an anti-obesity peptide, which is in Phase I clinical trial for disrupting the blood supply that supports unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue; ARC-520, an RNAi-based therapeutic to treat chronic HBV infection; and CALAA-01, an RNAi-based therapeutic that has completed a Phase IB clinical trial, which targets solid tumors. Its products also comprise CRLX-101 for NSC lung cancer; and Tubulin Inhibitor for oncology. The company, formerly known as InterActive Group, Inc., was founded in 2003 and is headquartered in Pasadena, California.
Biology Organ Systems Solid Tumors Infection Molecular Biology Obesity Genetics Gene Expression Hepatitis B RNA Molecular Genetics Apoptosis Biochemistry Chronic Hepatitis B Virus

Is ARWR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 73.72
52 Week Low 10.41
Average Volume 2,049,590
200-Day Moving Average 30.31
50-Day Moving Average 46.71
20-Day Moving Average 60.67
10-Day Moving Average 67.84
Average True Range 4.71
ADX 52.19
+DI 29.34
-DI 11.96
Chandelier Exit (Long, 3 ATRs ) 59.59
Chandelier Exit (Short, 3 ATRs ) 57.03
Upper Bollinger Band 79.18
Lower Bollinger Band 42.16
Percent B (%b) 0.68
BandWidth 61.02
MACD Line 6.84
MACD Signal Line 6.98
MACD Histogram -0.1445
Fundamentals Value
Market Cap 5.03 Billion
Num Shares 74.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -105.19
Price-to-Sales 11.15
Price-to-Book 2.81
PEG Ratio -1.10
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 73.41
Resistance 3 (R3) 73.61 71.78 72.40
Resistance 2 (R2) 71.78 70.23 71.68 72.06
Resistance 1 (R1) 69.55 69.27 68.64 69.35 71.72
Pivot Point 67.72 67.72 67.26 67.62 67.72
Support 1 (S1) 65.49 66.17 64.58 65.29 62.92
Support 2 (S2) 63.66 65.21 63.56 62.58
Support 3 (S3) 61.43 63.66 62.25
Support 4 (S4) 61.23